The company sold 20 million new shares at $0.40 per share. It plans to use the funds to ramp up marketing efforts for its Ortho-ATI product, a stem cell therapy, in Australia as well as finalize the development of CelGro, a collagen-based scaffold for tissue repair in reconstructive surgical applications.
Part of the funds will be used to maintain regulatory approvals for Ortho-ATI and Ortho-ACI in Australia, according to the report.
More Articles on Devices:
1st reverse shoulder surgery with DJO Surgical’s blended vitamin E polyethylene performed
Can generic orthopedic device start-ups disrupt medtech giants?
Smith & Nephew introduces lesser toe repair system
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
